Blue Trust Inc. Purchases 1,844 Shares of Hims & Hers Health, Inc. $HIMS

Blue Trust Inc. raised its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 95.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,767 shares of the company’s stock after buying an additional 1,844 shares during the quarter. Blue Trust Inc.’s holdings in Hims & Hers Health were worth $188,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Hims & Hers Health in the first quarter valued at $41,000. Larson Financial Group LLC boosted its position in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares during the period. Webster Bank N. A. boosted its position in Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after purchasing an additional 630 shares during the period. Finally, Tsfg LLC bought a new position in Hims & Hers Health during the first quarter worth $46,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Soleil Boughton sold 2,637 shares of the firm’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $54.38, for a total transaction of $143,400.06. Following the completion of the sale, the insider directly owned 161,130 shares of the company’s stock, valued at $8,762,249.40. This trade represents a 1.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $506,060.50. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at $8,581,970. The trade was a 5.57% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,561,799 shares of company stock worth $80,686,085. 13.71% of the stock is owned by insiders.

Hims & Hers Health Trading Up 16.2%

NYSE HIMS opened at $62.79 on Thursday. The firm has a market capitalization of $14.19 billion, a P/E ratio of 78.49, a PEG ratio of 3.69 and a beta of 2.25. The business has a fifty day simple moving average of $50.89 and a 200 day simple moving average of $48.43. Hims & Hers Health, Inc. has a 12 month low of $18.33 and a 12 month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. During the same period in the prior year, the business earned $0.06 earnings per share. The company’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HIMS shares. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Finally, Truist Financial cut their price target on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Reduce” and an average price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.